[mft_]

The approach is in the public domain - in that it could be attempted by anyone else.

According to the paper, these were the two drugs used:

* "CpG SD-101 was provided by Dynavax Technologies"

* "Fc-silent Anti-OX40 (CD134) mAb was purchased from Absolute Antibody"

SD-101 is already in clinical trials. http://www.dynavax.com/our-pipeline/cancer-immunotherapy/sd1... The anti-OX40 was a laboratory antibody, presumably as this was for a study in mice. However, there are various anti-OX-40 molecules in clinical trials, which could be used.

To get clinical trials going with this approach isn't a matter of patents - it's a matter of one or two companies (depending on ownership of suitable molecules) deciding its something they want to do, and then doing it. My guess is that Dynavax will already be exploring this.